| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_0421dfb6fd7a9c78d44ecf022dd9e93f
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_fa4325f4f26506b0c80611ff1f776610
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bc07aecb330595e4c51aa768af5786f6
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_71d28a8ce0e41a167ed6064dd32d979c
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_713e660a5c8e279c938824a84ed8ee40 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C2601-08 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D493-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D311-94
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D307-935
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07C405-00 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D311-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-93 |
| filingDate |
2011-04-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2012-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2725cae425e9eac20862023962c98e5b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_2c552b269e1b104a273ce7516c666cdc
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0c7ccb1e40424d45c91a2f1faea8cd4
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_277c729d9f29d456218776220040eeb0 |
| publicationDate |
2012-11-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-8309744-B2 |
| titleOfInvention |
Prostaglandin synthesis and intermediates for use therein |
| abstract |
Fused cyclopentane—4-substituted 3,5-dioxalane lactone compounds useful as an intermediate in the synthesis of prostaglandin analogs are provided. The compounds have the formula A: n nwherein R represents an aryl group such as p-methoxyphenyl.n n This compound can be reacted with a lower alkyl aluminum compound to open the dioxalane ring and reduce the lactone to lactol, without over-reducing to diol. The resulting compound can be functionalized to insert chemical side groups of target prostaglandins, adding the required α-side chain and then the required ω-side chain sequentially and independently of each other. The compounds and process are particularly suitable for preparing lubiprostone. |
| isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013072695-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-2013184476-A1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-10457623-B1
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-3594201-A1 |
| priorityDate |
2008-08-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |